Tandem Diabetes Care TNDM Accounts Receivable, Credit Loss Expense (Reversal)
Accounts Receivable, Credit Loss Expense (Reversal) at other companies
Other financials
Where this comes from
Reported directly by Tandem Diabetes Care in its filing.
Tagged under the XBRL concept us-gaap:ProvisionForDoubtfulAccounts.
The official record: Tandem Diabetes Care’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tandem Diabetes Care's accounts receivable, credit loss expense (reversal).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tandem Diabetes Care's accounts receivable, credit loss expense (reversal)?
- Tandem Diabetes Care (TNDM) reported accounts receivable, credit loss expense (reversal) of $2.11M in Q1 2026.
- How has Tandem Diabetes Care's accounts receivable, credit loss expense (reversal) changed year-over-year?
- Tandem Diabetes Care's accounts receivable, credit loss expense (reversal) increased by 47.4% year-over-year, from $1.43M to $2.11M.
- What is the long-term trend for Tandem Diabetes Care's accounts receivable, credit loss expense (reversal)?
- Over 4 years (2021 to 2025), Tandem Diabetes Care's accounts receivable, credit loss expense (reversal) has grown at a 42.0% compound annual growth rate (CAGR), from $2.33M to $9.48M.